Lebrikizumab Provides Stable Itch Response With No or Minimal Fluctuations up to One Year in Patients With Atopic Dermatitis

Main Article Content

James Del Rosso
Gil Yosipovitch
Sonja Ständer
Jonathan Silverberg
Andreas Wollenberg
Peter A. Lio
Jose Manuel Carrascosa
Gaia Gallo
Marta Casillas
Evangeline Pierce
Yuxin Ding
Zhenhui Xu
Helena Agell
Linda Stein Gold

Keywords

Lebrikizumab, atopic dermatitis, itch

References

1. Okragly AJ, et al. Dermatol Ther (Heidelb). 2023;13:1535-1547. ​

2. Ratnarajah K, et al. J Cutan Med Surg. 2021;25:315-328. ​

3. Silverberg JI, et al. N Engl J Med. 2023;388:1080-1091. ​

4. Blauvelt A, et al. Br J Dermatol. 2023;188:740-748.​

5. Silverberg JI, et al. Presented at: RAD 2023. ​

6. Yosipovitch G, et al. Br J Dermatol. 2019;181:761-769.​

7. Yosipovitch G, et al. Br J Dermatol. 2022;186:1047-1049.

Similar Articles

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 9 10 > >>